Sellas Stock 346% Year Near Final REGAL Deaths Ahead
Sellas Life Sciences has surged 346% over the past year as its REGAL trial for a WT1-targeting cancer vaccine moves t...
A concise guide to spotting tax-friendly dividend ETFs, including key metrics and quick tips to boost after-tax performance.
22,830 articlesSellas Life Sciences has surged 346% over the past year as its REGAL trial for a WT1-targeting cancer vaccine moves t...
Inside ENAVATE's disclosed stake in Zenas BioPharma and why the Obexelimab pipeline is grabbing attention. Learn what...
Credit conditions are tightening ahead of any Fed move, driven by higher bond yields and a wave of AI financing. Inve...
In stock market today, march, Grab surprised investors with a substantial buyback and a bold Foodpanda expansion. Thi...
Quantum computing stocks ionq, Rigetti, and D-Wave have captured investor imaginations with big promises and big vola...
CrossCountry Mortgage pushes back in the bid for Two Harbors, saying a fully financed cash offer backed by Citi will ...
Two-thirds of the S&P 500 have reported, and the results are surprisingly strong. This could mean smoother gains for ...
When Road releases its Q2 results, the transcript hides clues about growth and risk. This guide translates the road 2...
NVIDIA stock investors just received a wave of optimism from analysts who see substantial upside as AI adoption accel...
Halozyme’s halo (HALO) 2026 earnings landscape hinges on ENHANZE collaborations, pipeline milestones, and disciplined...
As AI accelerates, a handful of chipmakers stand to benefit the most. This guide highlights four brilliant chip stock...
Meta Platforms posts stronger growth in Q1 2026, lifting revenue and margins while the stock trades at a meaningful d...